Tags

Type your tag names separated by a space and hit enter

Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands.
J Recept Signal Transduct Res. 1995 Jan-Mar; 15(1-4):643-50.JR

Abstract

Previous work has suggested the existence of subtypes of the delta opioid receptor (DOR) which have been termed delta1 and delta2. [D-Ala2, Glu4]deltorphin has been suggested to selectively elicit antinociception via the delta2 receptor while [D-Pen2, D-Pen5]enkephalin (DPDPE) is thought to act via the delta1 receptor. Treatment with an antisense oligodeoxynucleotide (oligo) directed towards the N-terminal portion of the cloned DOR has been demonstrated to selectively inhibit the antinociceptive actions of [D-Ala2, Glu4]deltorphin, but not of DPDPE, suggesting that the cloned DOR corresponds to that pharmacologically defined as delta2. Here, an antisense oligo (or a mismatch sequence) was designed to target a conserved region of the cloned mu, delta and kappa opioid receptor. These oligos were employed in order to determine whether the antinociceptive effects of [D-Ala2, Glu4]deltorphin, as well as DPDPE, could be inhibited. The data indicate that the antinociceptive actions of both ligands were inhibited by treatment with this antisense, but not with the mismatch oligo. Taken together, the results of the treatments with oligos directed towards the N-terminal portion of the cloned DOR and with that directed to the conserved region of the opioid receptors suggest that (a) DPDPE effects are mediated by a subtype of the DOR which shares a domain common to the cloned opioid receptors, and (b) the N-terminal region differs between these putative DOR subtypes.

Authors+Show Affiliations

Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8903970

Citation

Lai, J, et al. "Treatment With Antisense Oligodeoxynucleotide to a Conserved Sequence of Opioid Receptors Inhibits Antinociceptive Effects of Delta Subtype Selective Ligands." Journal of Receptor and Signal Transduction Research, vol. 15, no. 1-4, 1995, pp. 643-50.
Lai J, Bilsky EJ, Porreca F. Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands. J Recept Signal Transduct Res. 1995;15(1-4):643-50.
Lai, J., Bilsky, E. J., & Porreca, F. (1995). Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands. Journal of Receptor and Signal Transduction Research, 15(1-4), 643-50.
Lai J, Bilsky EJ, Porreca F. Treatment With Antisense Oligodeoxynucleotide to a Conserved Sequence of Opioid Receptors Inhibits Antinociceptive Effects of Delta Subtype Selective Ligands. J Recept Signal Transduct Res. 1995 Jan-Mar;15(1-4):643-50. PubMed PMID: 8903970.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands. AU - Lai,J, AU - Bilsky,E J, AU - Porreca,F, PY - 1995/1/1/pubmed PY - 1995/1/1/medline PY - 1995/1/1/entrez SP - 643 EP - 50 JF - Journal of receptor and signal transduction research JO - J Recept Signal Transduct Res VL - 15 IS - 1-4 N2 - Previous work has suggested the existence of subtypes of the delta opioid receptor (DOR) which have been termed delta1 and delta2. [D-Ala2, Glu4]deltorphin has been suggested to selectively elicit antinociception via the delta2 receptor while [D-Pen2, D-Pen5]enkephalin (DPDPE) is thought to act via the delta1 receptor. Treatment with an antisense oligodeoxynucleotide (oligo) directed towards the N-terminal portion of the cloned DOR has been demonstrated to selectively inhibit the antinociceptive actions of [D-Ala2, Glu4]deltorphin, but not of DPDPE, suggesting that the cloned DOR corresponds to that pharmacologically defined as delta2. Here, an antisense oligo (or a mismatch sequence) was designed to target a conserved region of the cloned mu, delta and kappa opioid receptor. These oligos were employed in order to determine whether the antinociceptive effects of [D-Ala2, Glu4]deltorphin, as well as DPDPE, could be inhibited. The data indicate that the antinociceptive actions of both ligands were inhibited by treatment with this antisense, but not with the mismatch oligo. Taken together, the results of the treatments with oligos directed towards the N-terminal portion of the cloned DOR and with that directed to the conserved region of the opioid receptors suggest that (a) DPDPE effects are mediated by a subtype of the DOR which shares a domain common to the cloned opioid receptors, and (b) the N-terminal region differs between these putative DOR subtypes. SN - 1079-9893 UR - https://www.unboundmedicine.com/medline/citation/8903970/Treatment_with_antisense_oligodeoxynucleotide_to_a_conserved_sequence_of_opioid_receptors_inhibits_antinociceptive_effects_of_delta_subtype_selective_ligands_ L2 - https://www.tandfonline.com/doi/full/10.3109/10799899509045246 DB - PRIME DP - Unbound Medicine ER -